Nvidia stock drops as Microsoft benefits from AI

Key Takeaways

• Eli Lilly has partnered with InSilico Medicine in a drug discovery deal potentially worth up to $2.75 billion, including an initial $115 million payment, to accelerate medication development using AI.
• Eli Lilly plans to invest $3 billion in China over the next decade, indicating a broader strategic focus on the region and AI.
• NVIDIA's stock valuation has dropped significantly, losing over $800 billion in market value, despite strong underlying business performance and rising gross margins.
• GXO Logistics is expanding its AI-driven operations, including a new Hasbro distribution center and autonomous truck pilots, utilizing its GXO IQ platform and collaborating with NVIDIA.
• Alnylam Pharmaceuticals is using AI, in partnership with Viz.ai, to improve the early diagnosis and treatment of transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM).
• CH Robinson achieved higher profits in 2025 by investing in AI and automation, which led to reduced operating costs and headcount despite a decrease in revenue.
• Bank of America reinstated coverage of Microsoft with a 'Buy' rating, positioning it as a key beneficiary of AI monetization.
• Qodo secured $70 million in Series B funding to verify AI-generated code, working with major enterprises like Nvidia and Walmart to ensure accuracy and reliability.
• SurePath AI is focusing on zero-trust security to accelerate enterprise AI adoption, particularly within regulated industries.
• ITC Properties is investing US$2 million in NScale, an AI-focused hyperscaler, to build expertise in AI and digital infrastructure.

Eli Lilly partners with InSilico for AI drug discovery deal

Eli Lilly has agreed to a deal with AI-driven biotech company InSilico that could be worth up to $2.75 billion. This partnership aims to speed up the discovery and development of new medications using artificial intelligence. The agreement includes an initial payment of $115 million, with more payments possible based on future success. InSilico's AI platform helps identify potential drug targets for diseases. This collaboration shows Eli Lilly's growing focus on using AI in healthcare.

Eli Lilly partners with AI firm for drug development

Drug maker Eli Lilly has signed a deal potentially worth over $2 billion with an artificial intelligence firm. This partnership will focus on discovering and developing new drugs using AI technology. The agreement includes an upfront payment of $115 million. The collaboration aims to reshape how medications are found and created. This move highlights the growing role of AI in the pharmaceutical industry.

Eli Lilly partners with AI firm for drug development

Pharmaceutical giant Eli Lilly has entered into a multi-billion dollar agreement with an artificial intelligence company to develop new drugs. The partnership will utilize the firm's Pharma.AI platform to discover and create medications. The deal includes an initial payment of $115 million and could exceed $2 billion in total value. This collaboration aims to transform the process of drug discovery and development. It underscores the increasing integration of AI in the pharmaceutical sector.

Eli Lilly's AI drug development deal boosts stock

Eli Lilly has finalized a $2.75 billion deal with Hong Kong-based Insilico, an AI company, to develop drugs using artificial intelligence. This partnership is expected to significantly speed up drug discovery timelines. Eli Lilly plans to invest $3 billion in China over the next decade, with about 3% of its revenue currently coming from the region. The stock has received a positive outlook from Wall Street analysts. This move signals a major push by Eli Lilly into AI-driven pharmaceutical research.

Eli Lilly and Insilico deepen AI drug discovery partnership

Eli Lilly is expanding its collaboration with Insilico Medicine, signing a new drug discovery and development deal potentially worth up to $2.75 billion. This follows an initial AI software licensing agreement three years ago. The new accord includes a $115 million upfront payment and potential milestone payments. Insilico's AI platform aims to identify targets for diseases with significant unmet needs. The partnership grants Lilly a worldwide license for preclinical oral therapeutics and joint R&D efforts.

Alnylam uses AI to improve heart disease diagnosis

Alnylam Pharmaceuticals is launching an initiative using AI to help doctors find and treat transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) earlier. They are partnering with Viz.ai to integrate an AI algorithm into clinical workflows through the AWARE study across five US health systems. Alnylam is also supporting an American Heart Association program to improve ATTR-CM diagnosis and care pathways. These efforts aim to help more patients receive timely treatment. While supportive of earlier diagnosis, these initiatives do not significantly alter the company's near-term focus on revenue and margins.

GXO Logistics expands AI-driven warehouses and truck pilots

GXO Logistics is advancing its use of AI in logistics by opening Hasbro's new distribution center in Georgia and piloting an autonomous truck in France. These operations utilize GXO IQ, their AI platform, and collaborations with companies like KION and NVIDIA. The company believes outsourced, tech-heavy logistics will grow and aims to improve margins through automation. The Hasbro facility is a key example of GXO IQ in action, demonstrating the potential productivity benefits of AI. However, integrating new technology and managing leadership changes remain key challenges.

NVIDIA valuation drops below S&P 500 amid market concerns

NVIDIA's stock valuation has fallen to its lowest point since early 2019, trading below the S&P 500's multiple. This decline is driven by fears of war, inflation, and questions about the pace of AI spending. The chipmaker's stock has dropped nearly 20% from its peak, losing over $800 billion in market value. Despite these pressures, NVIDIA's business performance remains strong with rising gross margins and increasing earnings estimates. Some analysts still view the stock as a buy due to its lower valuation compared to the market.

NVIDIA stock price falls to seven-year low

NVIDIA's price-to-earnings (PE) ratio has dropped to its lowest level since before the AI boom, trading below the S&P 500 average. This is due to global market worries including Middle East conflict, inflation, and concerns about AI spending. The company has lost over $800 billion in market value, though its gross margins remain strong at 75%. Analysts expect significant earnings growth for NVIDIA, leading some to consider the stock a bargain. Potential competition and rapid AI changes pose risks to its market leadership.

Protect your AI investments amid global uncertainty

Investors can protect their artificial intelligence portfolios in 2026 by focusing on essential AI infrastructure and services. Key areas include semiconductors, cloud computing, data management, cybersecurity, and specialized AI software. These sectors are expected to remain in demand despite potential economic headwinds like high oil prices and uncertain interest rates. While geopolitical and macroeconomic factors pose risks, the underlying growth of AI remains strong. Strategic investment in foundational AI elements can help navigate market turbulence.

ITC Properties invests in AI infrastructure via NScale

ITC Properties is making a strategic investment of US$2 million in NScale, an AI-focused hyperscaler, through a partnership. This deal represents about one-third of the partnership interests. The company views this as a way to build expertise in AI and digital infrastructure alongside its traditional assets. NScale is a UK-based company focused on AI infrastructure. This move aligns ITC Properties with the growing digital infrastructure sector. The deal is considered small and does not require public notification.

CH Robinson profits rise despite lower revenue with AI investment

CH Robinson reported higher profits in 2025 despite a revenue decrease, thanks to ongoing investments in AI and automation. These technologies helped reduce headcount and operating costs, leading to an 18.8% increase in operating income. Total revenue fell by 8.4% to US$16.23 billion, while costs and expenses decreased significantly. The company reduced its workforce by 11.5% as part of a restructuring to boost productivity. Despite these improvements, CH Robinson anticipates a challenging market due to geopolitical uncertainty and trade policy changes.

Analyst upgrades and downgrades in AI stocks

Several major analysts have adjusted their ratings on AI-related stocks. Bank of America reinstated coverage of Microsoft with a 'Buy' rating, seeing it as a key beneficiary of AI monetization. JPMorgan downgraded SAP to 'Neutral' due to slowing cloud growth and emerging risks. Bernstein downgraded Qualcomm to 'Market Perform' citing rising memory costs and weaker smartphone demand. These moves reflect ongoing shifts in investor sentiment and strategic assessments within the AI sector. Analysts are closely watching AI's impact on infrastructure, applications, and hardware.

AI tools make investing easier for individuals

Artificial intelligence is making investing more accessible and manageable for everyday people. While robots won't fully control finances, AI tools offer smarter decision-making support. These platforms help users define goals and risk tolerance, then suggest suitable stocks and strategies. AI can also build diversified portfolios and recommend adjustments over time. This technology simplifies research, portfolio building, and financial education, empowering individuals in their investment journey.

Qodo raises $70M for AI code verification

Qodo has secured $70 million in Series B funding to focus on verifying code generated by artificial intelligence. As AI tools produce vast amounts of code, ensuring its accuracy and reliability is becoming a challenge. Qodo's platform helps enterprises build trust in AI-generated code by analyzing how changes affect entire systems. The company works with major enterprises like Nvidia and Walmart. This funding will help Qodo address the growing need for quality assurance in AI-driven software development.

SurePath AI accelerates enterprise AI adoption with security focus

SurePath AI is emphasizing security to speed up the adoption of artificial intelligence in businesses. The company highlights zero-trust security for AI agents and a financial services use case. They suggest a shift from blocking AI to enabling it, moving from risk management to acceleration within 30-60 days. SurePath AI positions itself at the intersection of cybersecurity and enterprise AI, especially in regulated industries. Their focus on security-led acceleration could expand their market within compliance-focused companies.

Sources

• Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. What It Means for the Stock.
• Eli Lilly signs $2 billion deal to develop drugs using artificial intelligence
• Eli Lilly signs $2 billion deal to develop drugs using artificial intelligence
• Eli Lilly Stock (LLY) Gets a Boost from Plan to Make Drugs Using AI
• Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B
• AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY)
• How Investors Are Reacting To GXO Logistics (GXO) Expanding AI-Driven Distribution With New Flagship Facilities
• NVIDIA Valuation Drops Below S&P 500 Amid War Tensions and AI Trade Pressure
• Nvidia's PE sinks to seven-year low as war and AI angst weigh
• Oil over $100, a war in the Middle East, and the Fed on hold. Here's how to protect your artificial intelligence (AI) portfolio in 2026
• ITC Properties Makes Strategic AI Infrastructure Investment via NScale Partnership
• CH Robinson profits rise despite revenue fall amid AI investment
• 5 big analyst AI moves: Downgrades for SAP and Qualcomm; Arm lifted to Buy
• Did AI just make investing easier for everyone?
• Qodo raises $70M for code verification as AI coding scales
• SurePath AI Emphasizes Security-Led Acceleration of Enterprise AI Adoption